Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
23:03
Meteorologists announce strong winds in 13 counties and a significant cooling, with rain and snowfall in the mountains until Thursday
22:57
Zelensky and Trump have agreed to meet in New York / “The meeting could change many things”
22:44
Traian Băsescu defends Siegfried Mureșan and rejects accusations that the MEP was a German spy
22:32
Claudiu Manda announces that the PSD will not vote for the Siegfried Mureșan government and criticizes the statements made by the candidate for the position of prime minister
22:17
Russia’s Electoral Commission reports more than 1,000 DDoS attacks on infrastructure involved in the parliamentary elections
See more news